国产吉西他滨联合重组人血管内皮抑制素二线治疗晚期胰腺癌的临床观察

目的：观察国产吉西他滨（泽菲）联合重组人血管内皮抑制素（恩度）二线治疗晚期胰腺癌的近期疗效及毒性反应。方法：15例患者均经病理学或影像学确诊为胰腺癌，全组病例均采用泽菲联合恩度治疗：泽菲1000mg／m^2，静滴30分钟，每周1次，连用2周；恩度7．5mg／m^2，一般为15rag／次，加入生理盐水500ml中缓慢静脉滴注，滴注时间为3～4小时，第1～14天连续给药。每3周重复。结果：15例患者中，可评价疗效患者14例，无CR病例，PR1例，SD4例，PD9例，疾病控制率35．7％（5／14）。临床受益反应率40．0％（6／15）。主要毒副反应为骨髓抑制，恶心呕吐以及心电图异常。结论：泽菲联合恩度方案治疗晚期胰腺癌疗效较好，毒副反应轻，耐受性良好，值得进一步研究。

Observation of domestic gemcitabine plus endostar in the second line of treatment of patients with advanced pancreatic cancer

Objective：To observe the short-time effect and toxic reaction of domestic gemcitabine plus endostar in the second line of treatment of patients with advanced pancreatic cancer. Methods：Fifteen histologically or cytologically confirmed advanced pancreatic cancer patients were treated with domestic gemcitabine plus endostar （domestic gemcitabine 1 000mg/m^2 on day 1 and day 8, 15mg endostar solved in 500ml of normal saline was slow intravenously dropped from day 1 to day 14） every 3 weeks. Results：Among 15 patients, 14 were evaluated with 35.7% disease control rate（ DCR）, 1 case have got PR,4 SD,9 PD. Clinical beneficial rate（CBR） was 40.0%. The main toxicities were marrow restraint, gastrointestinal reaction and electrocardiogram dysfunction. Conclusion： The domestic gemcitabine plus endostar in the second line of treatment of patients with advanced pancreatic cancer has a good short-time effects, slight advere reaction and patients tolerate well, it is worth studying further.